- Home
- HUMA vs ECBK Comparison
HUMA vs ECBK Comparison
Compare HUMA & ECBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HUMA | ECBK |
|---|---|---|
| Founded | 2004 | 1919 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.7M | 182.5M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | HUMA | ECBK |
|---|---|---|
| Price | $0.36 | $20.62 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $1.63 | N/A |
| AVG Volume (30 Days) | ★ 4.8M | 6.6K |
| Earning Date | 11-11-2026 | 10-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 79.37 | ★ 95.83 |
| EPS | N/A | ★ 0.77 |
| Revenue | ★ $2,038,000.00 | $598,000.00 |
| Revenue This Year | $72.32 | N/A |
| Revenue Next Year | $518.79 | N/A |
| P/E Ratio | ★ N/A | $26.60 |
| Revenue Growth | N/A | ★ 3.64 |
| 52 Week Low | $0.36 | $14.83 |
| 52 Week High | $1.90 | $21.78 |
Technical Indicators
Market Signals| Indicator | HUMA | ECBK |
|---|---|---|
| Relative Strength Index (RSI) | 18.00 | 43.79 |
| Support Level | N/A | $20.03 |
| Resistance Level | $0.75 | $20.79 |
| Average True Range (ATR) | 0.03 | 0.51 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 0.04 | 26.50 |
Price Performance
Historical ComparisonAbout HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
About ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company. The firm, through its subsidiary, engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, multifamily real estate loans, construction and land loans, and home equity lines of credit.